Mixed Urinary Incontinence

Summary

Introduction

Mixed Urinary Incontinence (MUI) affects over 10% of women, with women suffering from unpleasant symptoms of both urge urinary incontinence (UUI) and stress urinary incontinence (SUI). At present, no pharmacological agent is able to effectively treat the symptoms of both UUI and SUI.

Scope

• Quantitative treatment data from 288 physicians based in US, Japan, France, Germany, Italy, Spain and UK; supported by key opinion leader comments
• Analysis of epidemiology, presentation and referral patterns, diagnostic assessment, and first- to third-line treatments for MUI
• Influences on treatment choice and perception of current drug therapies including darifenacin, solifenacin and duloxetine
• Evaluation of unmet needs and future outlook including awareness of R&D drug pipeline

Highlights

• Approximately only half of women with MUI seek treatment for their condition. Of these women, less than half receive an accurate diagnosis on first presentation to a physician. Drug manufacturers are therefore failing to maximize revenues. A need for better education of both patients and physicians exists.
• With approximately a third of patients most distressed by their SUI symptoms, opportunities still exist for manufacturers with a pharmacological treatment for SUI to establish themselves as physicians' first-line treatment option for MUI.
• Drug treatment rates are higher in MUI overall than in other urinary incontinence disorders, which may favor this market for novel product launches.

Reasons to Purchase

• Forecast product sales by understanding key aspects of MUI epidemiology, diagnosis and treatment
• Gain a better understanding of the challenges facing current and future players in the MUI market
• Identify physicians key concerns in MUI including unmet needs and the attributes that physicians believe are desirable for future treatments

Contents

• This product has been designed for delivery in a slide pack format (PowerPoint).
• Please select the slide pack option from the download menu at the side of the page
• Introduction
• Scope of this report
• Research and analysis highlights
• Key reasons to read this report
• Appendix A
  • Research methodology
  • Physician Sample breakdown
  • Urinary Incontinence and Overactive Bladder Insight Study - Physician Questionnaire
  • Section One Overview of Urinary Incontinence and overactive Bladder
  • Epidemiology
  • Presentation
  • Diagnosis
  • Referral pattern
  • Section Two Stress Urinary Incontinence
  • Diagnosis and treatment of SUI
  • Non-pharmacological treatment
  • Pharmacological treatment for SUI
  • Section Three Overactive Bladder With Urge Symptoms and/or Incontinence
  • Diagnosis and treatment of UUI
  • Pharmacological treatment for UUI
  • Diagnosis and treatment of 'dry OAB'
  • Pharmacological treatment for dry OAB
  • Section Four Mixed Stress/Urge Urinary Incontinence
  • Diagnosis and treatment of mixed SUI/UUI
  • Non-pharmacological treatment
  • Pharmacological treatment for mixed SUI/UUI
  • Section Five Interstitial Cystitis
  • Diagnosis and treatment of IC
  • Pharmacological treatment for IC
  • Section Six Drug Profiles
  • Section A: Drug influences on physicians' choice
  • Section B: The general treatment of urinary incontinence and overactive bladder
  • Contributing experts
  • US
  • Japan
  • Europe
• Appendix B
  • About Datamonitor
  • About Datamonitor Healthcare
  • About the CNS analysis team
  • Disclaimer